Taysha Gene Therapies (TSHA) News Today $1.94 -0.53 (-21.34%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9.3% - What's Next?Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.3% - What's Next?May 5 at 3:33 AM | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from BrokeragesMay 5 at 3:29 AM | americanbankingnews.comAcuta Capital Partners LLC Cuts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Acuta Capital Partners LLC cut its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 58.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 884,244 shares ofMay 4 at 7:12 AM | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received an average rating of "Buy" from the eight ratings firms that are presently covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price objectiMay 2, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Makes New $8.65 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,000,000 shares of tMay 1, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)JMP Securities reiterated a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Monday.April 30, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday.April 30, 2025 | marketbeat.comRenaissance Technologies LLC Makes New $1.52 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Renaissance Technologies LLC purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 878,448 shares of the company's stock, valued at approxiApril 29, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Receives "Market Outperform" Rating from JMP SecuritiesApril 29, 2025 | americanbankingnews.comCantor Fitzgerald Reiterates Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 29, 2025 | americanbankingnews.comAvoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Avoro Capital Advisors LLC increased its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,999,999 shares of the company's stock after acquiring an addApril 23, 2025 | marketbeat.comB Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)B Group Inc. purchased a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 965,556 shares of the company's stock, valued at apprApril 23, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,643,755 shares of the company's stock afterApril 21, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Vanguard Group Inc. raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,906,764 shares of the company's stock after acquiringApril 20, 2025 | marketbeat.comTaysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited OpportunityApril 16, 2025 | seekingalpha.comNorges Bank Takes $2.53 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Norges Bank bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,461,120 shares of the company's stock, valued at approximately $2,528,000. NorgesApril 14, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by AnalystsShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received an average recommendation of "Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price targetApril 7, 2025 | marketbeat.comWells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)April 5, 2025 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comIs Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?March 19, 2025 | msn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from AnalystsShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are presently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The averageMarch 11, 2025 | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on TuesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667936)March 11, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comTSHA FY2025 EPS Forecast Raised by Cantor FitzgeraldTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a research report issued on Thursday, February 27th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will pMarch 3, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday.February 28, 2025 | marketbeat.comTruist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)February 28, 2025 | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Receives "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday.February 27, 2025 | marketbeat.comQ4 2024 Taysha Gene Therapies Inc Earnings CallFebruary 27, 2025 | finance.yahoo.comTaysha Gene Therapies Reports 2024 Financial ResultsFebruary 27, 2025 | tipranks.comTaysha Gene Therapies reports FY24 EPS (36c) vs (96c) last yearFebruary 26, 2025 | markets.businessinsider.comTaysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Quarterly Earnings ResultsTaysha Gene Therapies (NASDAQ:TSHA - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%.February 26, 2025 | marketbeat.comTaysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate UpdateFebruary 26, 2025 | globenewswire.comTaysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of EarningsFebruary 25, 2025 | finance.yahoo.comTaysha Gene Therapies (TSHA) Projected to Post Earnings on WednesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing earnings before the market opens on Wednesday, February 26, Financial Modeling Prep reports.February 21, 2025 | marketbeat.comTaysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26February 19, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3% - Time to Buy?Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 1.3% - Time to Buy?February 15, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received a consensus recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 yeaFebruary 14, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comTaysha Gene Therapies Is Showing Promise For Rett SyndromeJanuary 27, 2025 | seekingalpha.comEquities Analysts Set Expectations for TSHA FY2025 EarningsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Taysha Gene Therapies in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earniJanuary 22, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average rating of "Buy" from the eight analysts that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month target price among brJanuary 20, 2025 | marketbeat.comBarclays PLC Increases Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Barclays PLC boosted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 356.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 247,280 shares of the company's stock after purchasing an additional 193,046 sharJanuary 18, 2025 | marketbeat.comTaysha Gene Therapies' (TSHA) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Monday.January 6, 2025 | marketbeat.comTaysha Gene Therapies announces inducement grant under Nasdaq listing ruleJanuary 3, 2025 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comGeode Capital Management LLC Acquires 682,273 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Geode Capital Management LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 23.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,562,758 shaJanuary 3, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest UpdateTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 21,880,000 shares, an increase of 39.6% from the November 30th total of 15,670,000 shares. Based on an average trading volume of 4,270,000 shares, the short-interest ratio is currently 5.1 days.December 28, 2024 | marketbeat.com Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Media Mentions By Week TSHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSHA News Sentiment▼0.660.69▲Average Medical News Sentiment TSHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSHA Articles This Week▼83▲TSHA Articles Average Week Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TARS News BEAM News BLTE News VCEL News ARWR News RXRX News TVTX News SDGR News IBRX News ARQT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSHA) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredConfidential Economic AdvisoryI've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSHA Stock Free TSHA Stock Alerts